CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
London, United Kingdom and 24 other locations
therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 2, Phase 3
London, United Kingdom and 70 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Chelsea, London, United Kingdom and 44 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...
Phase 3
London, United Kingdom and 227 other locations
medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...
Phase 2
London, Kensington AND Chelsea, United Kingdom and 62 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
City of London, London, United Kingdom and 10 other locations
Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with p...
Phase 2
London, United Kingdom and 9 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
London, United Kingdom and 43 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
London, United Kingdom and 45 other locations
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...
Phase 2
London, England, United Kingdom and 56 other locations
Clinical trials
Research sites
Resources
Legal